Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Recruiting 2Not yet recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Gastrointestinal 8Other solid neoplasm 5Sarcoma 4Thoracic 2Genitourinary 2Head & Neck 1Gynecologic 1

Conditions

Advanced or Metastatic Solid Tumors 2Solid Tumor 1Advanced Solid Tumor 1Advanced Refractory Solid Tumors 1

Interventions

pembrolizumab 75Injections 67Carboplatin 38Pemetrexed 29Cisplatin 29Nivolumab 27Specimen Handling 24Interviews as Topic 24Cyclophosphamide 24atezolizumab 21tislelizumab 20Bevacizumab 20Paclitaxel 19Standard of Care 16Practice Guidelines as Topic 16fludarabine 15Docetaxel 15toripalimab 14Ipilimumab 14Educational Status 14Cetuximab 14Fluorouracil 13Oxaliplatin 12Etoposide 12olaparib 11durvalumab 11Methods 11Gemcitabine 11Early Intervention, Educational 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
envafolimab × Other solid neoplasm × 1 year × Clear all
NCT07562347 2026-05-01

ENCOMPASS STUD

IR INNOVATE RESEARCH PRIVATE LIMITED

Not yet recruiting
120 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT06074497 2026-04-29

This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy With Envafolimab in Patients With Advanced or Metastatic Solid Tumors.

Kangabio AUSTRALIA LTD PTY

Phase 1 Active not recruiting
54 enrolled
Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT07260305 2026-04-24

A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients

Kangabio AUSTRALIA LTD PTY

Phase 1 Recruiting
57 enrolled
Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT04891198 2026-03-25

ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors

3D Medicines

Phase 2 Recruiting
126 enrolled
Other solid neoplasm

Solid Tumor

NCT07327411 2026-01-08

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

Second Affiliated Hospital of Soochow University

Phase 2 Not yet recruiting
40 enrolled
Other solid neoplasm

Advanced Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡